Enterprise Value

3.618B

Cash

442.1M

Avg Qtr Burn

N/A

Short % of Float

4.74%

Insider Ownership

4.10%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DTX401 Details
Glycogen Storage Disease Type Ia

Big Mover™

Susp. Mover™

Phase 3

Data readout

DTX301 Details
Ornithine transcarbmylase deficiency

Phase 3

Update

UX143 (Setrusumab) Details
Osteogenesis imperfecta

Phase 2/3

Data readout

UX053 Details
Rare diseases, glycogen storage disease type III

Phase 1/2

Data readout

UX701 Details
Wilson's disease, Rare diseases

Phase 1/2

Data readout

GTX-102 Details
Angelman Syndrome

Phase 1/2

Interim update

UX111 (ABO-102) Details
Rare diseases, Sanfilippo Syndrome

Phase 1/2

Update